High‑dose dual therapy versus bismuth‑containing quadruple therapy for the treatment of Helicobacter pylori infection – A review of the strengths, weaknesses, and proposed solutions

Abstract

 

Helicobacter pylori is the principal cause of peptic ulcers, gastric cancer, and mucosa‑associated lymphoid tissue lymphoma. The first treatment to H. pylori infection is dual therapy (a bismuth compound plus metronidazole). On the launch of omeprazole in 1988, dual therapy became omeprazole and amoxicillin (low dose). The poor H. pylori eradication rates by either bismuth‑based or low‑dose dual therapy drove more combinations of antibiotics were needed. Antibiotic resistance, especially clarithromycin and metronidazole, has made bismuth‑containing quadruple therapy (BCQT) a savior for first‑line and second‑line treatments. However, its complicated dosing regimen commonly causes more adverse events and poor drug compliance. Thus, high‑dose dual therapy (HDDT) has been re‑arising. This article reviews the strengths and weaknesses of HDDT versus BCQT with proposed solutions.

 

Keywords: Bismuth‑containing quadruple therapy, Helicobacter pylori, High dose dual therapy